Clinical trials: ST-elevation Myocardial Infarction (STEMI)
ST-elevation Myocardial Infarction
MINI-AMI: Minimizing Infarct Size With Impella 2.5 Following PCI for Acute Myocardial Infarction
A prospective, randomized, controlled multi-site feasibility trial to assess the potential role of the IMPELLA® 2.5 System in reducing infarct size in patients with ST-elevation myocardial infarction (STEMI)
- Trial name
- MINI-AMI (NCT01319760)
- Testing
- Impella 2.5 support, Standard of care (Control)
- Volunteers
- 5 people
- Sponsor
- Abiomed Inc.
Myocardial Infarction, Myocardial Ischemia
Time for a Diagnostic Paradigm Shift From STEMI/NSTEMI to OMI/NOMI
The investigators hypothesize that occlusion myocardial infarction(MI)/non-occlusion MI approach to MI treatment will better predict acute coronary occlusion on coronary angiography, better limit infarct size, better preserve…
- Conditions
- Myocardial Infarction, Myocardial Ischemia, Acute Coronary Syndrome, Diagnosis
- Trial name
- DIFOCCULT-3 (NCT06570759)
- Testing
- Early intervention for OMI, Standard early intervention for STEMI, Standard delayed intervention for NSTEMI
- Where
- 18 sites in Turkey (Türkiye)
- Volunteers
- 6,000 people
- Sponsor
- Başakşehir Çam & Sakura City Hospital
Familial Hypercholesterolemia, Familial Hypercholesterolemia Due to Genetic Defect of Apolipoprotein B
Advancing Cardiac Care Unit-based Rapid Assessment and Treatment of hypErcholesterolemia
ACCURATE will test the hypothesis that opportunistic genetic testing for Familial Hypercholesterolemia (FH) in patients admitted to hospital with an acute coronary syndrome will increase the diagnosis of FH and will impact…
- Conditions
- Familial Hypercholesterolemia, Familial Hypercholesterolemia Due to Genetic Defect of Apolipoprotein B, Familial Hypercholesterolemia Due to Heterozygous LDL Receptor Mutation, Familial Hypercholesterolemia - Heterozygous
- Trial name
- ACCURATE (NCT05218005)
- Testing
- Research-based genetic test for Familial Hypercholesterolemia
- Where
- 2 sites in Canada
- Volunteers
- 140 people
- Sponsor
- University of British Columbia
Acute Coronary Syndromes
Controlled Level EVERolimus in Acute Coronary Syndromes
Acute myocardial infarction (AMI) constitutes the major cause of death in most nations and death rates and morbidity remain substantial in the years thereafter.
- Trial name
- CLEVER-ACS (NCT01529554)
- Testing
- Everolimus
- Where
- 8 sites in Germany, Switzerland
- Volunteers
- 150 people
- Sponsor
- University of Zurich
Primary Percutaneous Coronary Intervention
Thin Versus Thicker Strut Thickness Stents in Primary Percutaneous Intervention
1. To evaluate clinical safety of the device in terms of Deaths, any stroke and Myocardial Infarction up to 1 year in both study groups to prove non inferiority of biomime stent 2.
- Trial name
- NCT06914089
- Testing
- The BioMime is an ultra-thin strut (65 µm) SES that uses a cobalt-chromium platform with a unique hybrid design of open cells in the mid segment and closed cells at the edges
- Where
- Egypt
- Volunteers
- 146 people, healthy volunteers welcome
- Sponsor
- Assiut University
Essential Hypertension
Protective Effect of Beraprost Sodium Tablets on Reperfusion Therapy for Acute STEMI
Protective effect of Beraprost Sodium Tablets on coronary microcirculation function and ventricular remodeling after reperfusion therapy for acute ST segment elevation myocardial infarction
- Trial name
- NCT05103813
- Testing
- Beraprost Sodium Tablets
- Where
- China
- Volunteers
- 100 people
- Sponsor
- Shenzhen People's Hospital
STEMI - ST Elevation Myocardial Infarction
Correlation Between Triglyceride Glucose Index and Residual SYNTAX Score in STEMI Patients Undergoing PPCI
The goal of this study To check correlation between triglyceride glucose (TyG) index and residual SYNTAX score (RSS) in STEMI patients undergoing PPCI. 2.
- Trial name
- NCT06642259
- Testing
- Echocardiography
- Volunteers
- 185 people
- Sponsor
- Assiut University
Non-ST Elevation Myocardial Infarction, Acute Coronary Syndrome
One-hour Troponin in a Low-prevalence Population of Acute Coronary Syndrome
This study aims to evaluate if the 1-hour rule-in/rule-out algorithm for a high-sensitivity cardiac troponin T (hs-cTnT) is safe and effective for use in the primary care where the patients have a lower pretest probability of an…
- Conditions
- Non-ST Elevation Myocardial Infarction, Acute Coronary Syndrome, Angina, Unstable, NSTEMI - Non-ST Segment Elevation MI
- Trial name
- OUT-ACS (NCT02983123)
- Testing
- 1-hour hs-cTnT
- Where
- Norway
- Volunteers
- 1,750 people
- Sponsor
- Oslo University Hospital
STEMI - ST Elevation Myocardial Infarction, Glucagon-like Peptide-1
Plasma Glucagon-like Peptide-1 Levels and In-hospital Complications in ST-segment Elevation Myocardial Infarction
Glucagon-like peptide-1 (GLP-1), produced mainly in enteroendocrine cells, participates in energy homeostasis and glucose metabolism by regulating islet hormone secretion, gastrointestinal motility, and food intake, making GLP-1…
- Conditions
- STEMI - ST Elevation Myocardial Infarction, Glucagon-like Peptide-1, Bleeding, Complications
- Trial name
- NCT03314844
- Volunteers
- 564 people
- Sponsor
- Chinese PLA General Hospital
ST Elevation Myocardial Infarction
The Predictive Value of eGFR for Adverse Cardiovascular Events in Patients With STEMI
Estimated glomerular filtration rate(eGFR) is significantly reduced in patients with ST-segment elevation myocardial infarction (STEMI).
- Trial name
- NCT03984071
- Volunteers
- 3 people, healthy volunteers welcome
- Sponsor
- Dongying Zhang
Coronary Artery Disease, Coronary Stenosis
Assessing the Accuracy of the OptoWire DeuxTM in a Wire to Wire Comparison
The goal of the ACCURACY study is to assess the differences, if any, in FFR measurements made by the OptoWire Deux FFR guidewire by comparison of simultaneous data of two different OptoWire DeuxTM guidewires (group 1).
- Conditions
- Coronary Artery Disease, Coronary Stenosis, Atherosclerosis, Atherosclerosis, Coronary
- Trial name
- ACCURACY (NCT03815032)
- Testing
- Drift assessment of OptoWire Deux FFR wire (1), Drift assessment of OptoWire Deux FFR wire (2)
- Where
- Canada
- Volunteers
- 45 people
- Sponsor
- Centre hospitalier de l'Université de Montréal (CHUM)
Cardiovascular Diseases, NSTEMI
Cholesterol Lowering Via Bempedoic Acid/Ezetimibe, an ACL-Inhibiting Regimen in Acute Coronary Syndrome Study
The overall objective of the Cholesterol Lowering via Bempedoic Acid/Ezetimibe, an ACL-Inhibiting Regimen in Acute Coronary Syndrome ACS (CLEAR ACS) study is to determine the efficacy, safety, and tolerability of bempedoic…
- Conditions
- Cardiovascular Diseases, NSTEMI, STEMI
- Trial name
- NCT05263778
- Testing
- Bempedoic Acid / Ezetimibe Oral Tablet
- Where
- United States
- Volunteers
- 500 people
- Sponsor
- Kaiser Permanente
Reperfusion Injury, STEMI
Evaluation of Myocardial Effects of MTP-131 for Reducing Reperfusion Injury in Patients With Acute Coronary Events
The EMBRACE-STEMI trial was a Phase 2a prospective, multicenter, multinational randomized, double-blind, placebo-controlled study designed to assess the safety, tolerability, and efficacy of IV administered elamipretide (also…
- Trial name
- EMBRACE (NCT01572909)
- Testing
- Bendavia (MTP-131)
- Where
- 30 sites in United States, Germany and 2 more
- Volunteers
- 300 people
- Sponsor
- Stealth BioTherapeutics Inc.
Acute Myocardial Infarction
Right Ventricular Damage in Cardiovascular Magnetic Resonance
The purpose of this study is to determine the predictors of right ventricular damage (RVD) assessed by wall motion abnormalities, edema, myocardial salvage and delayed enhancement (DE)cardiac magnetic resonance imaging in acute…
- Trial name
- NCT01359306
- Volunteers
- 524 people
- Sponsor
- University of Leipzig
ST Elevation Myocardial Infarction (STEMI)
Drug-Eluting Balloon or Drug-Eluting Stent in Acute Myocardial Infarction: A Randomized Controlled Trial
The objective of the study is to compare drug-coated balloon (DCB) with the gold standard drug-eluting stent (DES) in percutaneous coronary intervention (PCI) for patients presenting with ST-elevation myocardial infarction…
- Trial name
- BOOST-AMI (NCT06746233)
- Testing
- Drug (paclitaxel) coated balloon (DCB), Second-generation Drug Eluting Stent (DES)
- Where
- 5 sites in Bosnia and Herzegovina, Serbia
- Volunteers
- 598 people
- Sponsor
- Institute of Cardiovascular Diseases, Vojvodina
ST Segment Elevation Myocardial Infarction
Early Assessment of QFR in STEMI-II
The study intends to provide new data on whether the noval method using quantitative flow ratio could assess microvascular dysfunction based on the previous study EARLY-MYO-QFR-I.
- Trial name
- EARLYmyoQFR-II (NCT03910400)
- Testing
- Computation of quantitative flow ratio
- Where
- China
- Volunteers
- 200 people
- Sponsor
- RenJi Hospital
STEMI
NLR AND CRP Useful as Cost-Effective Preliminary Prognostic Markers in ST-Elevation Myocardial Infarction
Acute myocardial infarction (AMI) is a serious and fatal cardiovascular emergency and considered the leading cause of mortality worldwide.
- Trial name
- NCT06491667
- Testing
- CBC, C-reactive protein
- Where
- Egypt
- Volunteers
- 100 people, healthy volunteers welcome
- Sponsor
- Sohag University
Non-ST Elevation Myocardial Infarction
Effect of the Interleukin-6 Receptor Antagonist Tocilizumab in Non-ST Elevation Myocardial Infarction
Acute coronary syndromes (ACS) are still associated with high morbidity and mortality, despite several improvements in their management.
- Trial name
- NCT01491074
- Testing
- Tocilizumab 280 mg, NaCl 0.9% 100 ml
- Where
- 2 sites in Norway
- Volunteers
- 120 people
- Sponsor
- Oslo University Hospital
STEMI
Patients Without Standard Modifiable Cardiovascular Risk Factors (SMuRF-less) and Their Prognosis After a ST-segment-Elevation Myocardial Infarction (STEMI)
The purpose of this study is to asses the prognosis of STEMI patients without standard modifiable risk factors of cardiovascular disease (diabetes mellitus, hyperlipidemia, hypertension and cigarette smoking) compare to patients…
- Trial name
- NCT05321667
- Where
- France
- Volunteers
- 500 people
- Sponsor
- Central Hospital, Nancy, France
Acute ST Elevation Myocardial Infarction
The Efficacy and Safety of rhTNK-tPA in Comparison With Alteplase(Rt-PA) as Fibrinolytic Therapy of Acute STEMI
This study is aiming to test the hypothesis that efficacy of rhTNK-tPA was not inferior to rt-PA with respect to the 30-day MACCE rates after fibrinolytic therapy for STEMI patients.
- Trial name
- NCT02835534
- Testing
- rhTNK-tPA, alteplase
- Where
- China
- Volunteers
- 818 people
- Sponsor
- CSPC Mingfule Pharmaceutical (Guangzhou) Co., Ltd.
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.